logo
  

Playtech Buys Privately-Held Yoyo Games

Playtech Plc (PTEC.L), an online gaming software supplier, announced Monday that it has acquired UK-based Yoyo Games Limited.

The purchase price for the deal is $16.4 million. The agreement calls for 30 percent of the consideration will be held in escrow for up to 36 months after closing to provide security in respect of claims. In addition, an earn-out consideration and a retention plan is expected to add a further $5.25 million to the aggregate cost.

Yoyo's key asset is Game Maker: Studio or GMS, a mobile driven cross-platform casual game development technology. This enables developers to create games using a single programming code and then publish them to run natively across most common platforms.

The company noted that GMS enables game developers to create cross-platform games in hours with a user-friendly intuitive platform. GMS has secured more than 750,000 registered games developers who currently use the platform on a freemium basis with chargeable add-ons.

The consideration for the acquisition will be funded from Playtech's existing cash balances.

Playtech said the deal is part of its strategy to penetrate the casual gaming space, which already includes Plamee - an internal games development team. This acquisition will enable the Company to further diversify its business, benefiting from a combined B2B/B2C offering focused on a strong and growing segment of the wider gaming market.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
IBSA Pharma Inc. is recalling 27 lots of TIROSINT-SOL (levothyroxine sodium) Oral Solution to the consumer level due to subpotency, the U.S. Food and Drug Administration said. TIROSINT-SOL is indicated for Hypothyroidism and Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression. Meanwhile, the recall does not apply to TIROSINT (levothyroxine sodium) capsules. The U.S. Food and Drug Administration approved GlaxoSmithKline LLC's Jesduvroq tablets (daprodustat) for anemia caused by chronic kidney disease or CKD for adults who have been receiving dialysis for at least four months. It is the first oral treatment for anemia, i.e., decreased number of red blood cells, in the given indication that has received FDA approval. German banking major Deutsche Bank AG reported Thursday a significantly higher profit in its fourth quarter and fiscal 2022, mainly reflecting a tax benefit in the U.S, despite weakness in Investment Bank and asset management revenues. The company said it recorded its highest annual profit, both before and after tax, since 2007. However, Deutsche Bank shares were losing around 4 percent...
RELATED NEWS
Follow RTT